David S. Boyer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
David S. Boyer has a total of 230 co-authors. Here are the top co-authors by number of shared publications:
- David M. Brown
Retina Consultants of Texas, Houston, TX, USA
4 shared publications Robert Vitti
Regeneron Pharmaceuticals, Tarrytown, New York
4 shared publicationsYenchieh Cheng
Regeneron Pharmaceuticals, Tarrytown, New York
4 shared publicationsAlyson J. Berliner
Regeneron Pharmaceuticals, Tarrytown, New York
3 shared publicationsKaren W. Chu
Regeneron Pharmaceuticals, Tarrytown, New York
3 shared publicationsW. Lloyd Clark
Department of Ophthalmology, University of South Carolina School of Medicine, Palmetto Retina Center, LLC, West Columbia
3 shared publications
Latest Publications
- Open Access
- 4 June 2026
- Published by Elsevier in Ophthalmology Retina
- Vol. 10 (10) , 1027-1035
Gildeuretinol Acetate versus Placebo for Geographic Atrophy Secondary to Age-Related Macular Degeneration
- 4 June 2026
- Published by Elsevier in Ophthalmology Retina
- Vol. 10 (10) , 1027-1035
Open AccessGildeuretinol Acetate versus Placebo for Geographic Atrophy Secondary to Age-Related Macular Degeneration
- Open Access
- 5 May 2026
- Published by Elsevier in Ophthalmology Retina
- Vol. 10 (9) , 966-974
Effects of Time from Diagnosis to Treatment and Baseline Vision on Retinal Vein Occlusion Outcomes in Aflibercept 2 mg Phase III Trials
- 5 May 2026
- Published by Elsevier in Ophthalmology Retina
- Vol. 10 (9) , 966-974
Open AccessEffects of Time from Diagnosis to Treatment and Baseline Vision on Retinal Vein Occlusion Outcomes in Aflibercept 2 mg Phase III Trials
- Open Access
- 1 May 2026
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. ume 20, 1-11
Efficacy of Continuous Pegcetacoplan Treatment for Subfoveal Geographic Atrophy in Age-Related Macular Degeneration: 36-Month Results from OAKS, DERBY, and GALE Open-Label Extension
To report efficacy of intravitreal pegcetacoplan treatment over 36 months in eyes with subfoveal geographic atrophy (GA). The GALE (NCT04770545) open-label extension trial adds 12 months of results to the 24-month Phase 3 OAKS (NCT03525613) and DERBY (NCT03525600) trials, representing up to 36 months of continuous pegcetacoplan treatment. They included a heterogeneous population of eyes with subfoveal GA (63%). Pegcetacoplan-treated eyes enrolling in GALE continued at the same interval of pegcetacoplan monthly (PM) or every other month (PEOM). Patients’ eyes in sham monthly or every-other-month arms crossed over to receive pegcetacoplan in GALE at the same interval (sham crossover). Consequently, projected sham, calculated from prior 24-month GA growth rate of sham-observed eyes in OAKS and DERBY averaged across four 6-month segments, was the comparator for the first 12 months of GALE (months 24–36). This analysis reports results of eyes with subfoveal GA at baseline. In eyes with subfoveal GA, 84% had best corrected visual acuity (BCVA) ≥20/200 and 38% had BCVA ≥20/63 at OAKS and DERBY baseline. Pegcetacoplan reduced subfoveal GA growth rate by 21% (p<0.0001) with PM and 19% (p=0.0001) with PEOM over 36 months. Increasing efficacy over time was noted between months 24 and 36; 31% reduction in subfoveal GA growth rate with PM and 25% reduction with PEOM (both p<0.0001) compared with projected sham. Microperimetry demonstrated significant reduction in formation of absolute scotomas with PM at 24 months (–2.5 number of scotomas formed; 95% confidence interval [CI]: –4.5, –0.4; p=0.0205) and 36 months (–4.0 number of scotomas formed; 95% CI: –6.8, –1.2; p=0.0050), compared to sham crossover in subfoveal GA. Safety profile in GALE was consistent with OAKS and DERBY. Long-term efficacy of pegcetacoplan in slowing GA progression was demonstrated over 36 months in eyes with subfoveal GA. Geographic atrophy (GA) is a progressive, permanent retinal degenerative disease that can lead to vision loss in patients over 60 years of age. This analysis was done to look at how pegcetacoplan, a treatment for GA, could help people with GA once it affected the center of their vision, called subfoveal GA. People with subfoveal GA are at risk of losing more of their central vision, which is important for reading, driving, and recognizing faces. Researchers looked at data from the GALE clinical trial, which followed people with GA for 3 years to see how well pegcetacoplan worked. They studied whether pegcetacoplan slowed down the growth of subfoveal GA and whether it helped lower the risk of forming new blind spots. People with subfoveal GA retained some vision that could be protected. In fact, 84% of them had mild or moderate visual impairment at baseline. Researchers found that pegcetacoplan slowed the growth of subfoveal GA over 3 years, whether it was given every month or every other month. They also found that pegcetacoplan may have lowered the risk of forming new blind spots in the eye. Pegcetacoplan treatment helped for people with subfoveal GA. Treating subfoveal GA is important because it can help people save the vision they still have and slow down further vision loss.
- 1 May 2026
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. ume 20, 1-11
Open AccessEfficacy of Continuous Pegcetacoplan Treatment for Subfoveal Geographic Atrophy in Age-Related Macular Degeneration: 36-Month Results from OAKS, DERBY, and GALE Open-Label Extension
To report efficacy of intravitreal pegcetacoplan treatment over 36 months in eyes with subfoveal geographic atrophy (GA). The GALE (NCT04770545) open-label extension trial adds 12 months of results to the 24-month Phase 3 OAKS (NCT03525613) and DERBY (NCT03525600) trials, representing up to 36 months of continuous pegcetacoplan treatment. They included a heterogeneous population of eyes with subfoveal GA (63%). Pegcetacoplan-treated eyes enrolling in GALE continued at the same interval of pegcetacoplan monthly (PM) or every other month (PEOM). Patients’ eyes in sham monthly or every-other-month arms crossed over to receive pegcetacoplan in GALE at the same interval (sham crossover). Consequently, projected sham, calculated from prior 24-month GA growth rate of sham-observed eyes in OAKS and DERBY averaged across four 6-month segments, was the comparator for the first 12 months of GALE (months 24–36). This analysis reports results of eyes with subfoveal GA at baseline. In eyes with subfoveal GA, 84% had best corrected visual acuity (BCVA) ≥20/200 and 38% had BCVA ≥20/63 at OAKS and DERBY baseline. Pegcetacoplan reduced subfoveal GA growth rate by 21% (p<0.0001) with PM and 19% (p=0.0001) with PEOM over 36 months. Increasing efficacy over time was noted between months 24 and 36; 31% reduction in subfoveal GA growth rate with PM and 25% reduction with PEOM (both p<0.0001) compared with projected sham. Microperimetry demonstrated significant reduction in formation of absolute scotomas with PM at 24 months (–2.5 number of scotomas formed; 95% confidence interval [CI]: –4.5, –0.4; p=0.0205) and 36 months (–4.0 number of scotomas formed; 95% CI: –6.8, –1.2; p=0.0050), compared to sham crossover in subfoveal GA. Safety profile in GALE was consistent with OAKS and DERBY. Long-term efficacy of pegcetacoplan in slowing GA progression was demonstrated over 36 months in eyes with subfoveal GA. Geographic atrophy (GA) is a progressive, permanent retinal degenerative disease that can lead to vision loss in patients over 60 years of age. This analysis was done to look at how pegcetacoplan, a treatment for GA, could help people with GA once it affected the center of their vision, called subfoveal GA. People with subfoveal GA are at risk of losing more of their central vision, which is important for reading, driving, and recognizing faces. Researchers looked at data from the GALE clinical trial, which followed people with GA for 3 years to see how well pegcetacoplan worked. They studied whether pegcetacoplan slowed down the growth of subfoveal GA and whether it helped lower the risk of forming new blind spots. People with subfoveal GA retained some vision that could be protected. In fact, 84% of them had mild or moderate visual impairment at baseline. Researchers found that pegcetacoplan slowed the growth of subfoveal GA over 3 years, whether it was given every month or every other month. They also found that pegcetacoplan may have lowered the risk of forming new blind spots in the eye. Pegcetacoplan treatment helped for people with subfoveal GA. Treating subfoveal GA is important because it can help people save the vision they still have and slow down further vision loss.
- 2 March 2026
- Published by Springer Nature in Eye
- Vol. 40 (6) , 751-754
Aflibercept 2 mg Biosimilar (aflibercept-ayyh, Pavblu): Experience of safety in clinical settings-APEX- safety study
- 2 March 2026
- Published by Springer Nature in Eye
- Vol. 40 (6) , 751-754
Aflibercept 2 mg Biosimilar (aflibercept-ayyh, Pavblu): Experience of safety in clinical settings-APEX- safety study
- Open Access
- 11 November 2025
- Published by Elsevier in Ophthalmology
- Vol. 133 (5) , 577-588
Intravitreal Aflibercept 8 mg for Diabetic Macular Edema
- 11 November 2025
- Published by Elsevier in Ophthalmology
- Vol. 133 (5) , 577-588
Open AccessIntravitreal Aflibercept 8 mg for Diabetic Macular Edema
- Open Access
- 14 August 2025
- Published by Elsevier in eClinicalMedicine
- Vol. 87, 103430
Safety and efficacy of MCO-010 optogenetic therapy in patients with Stargardt disease in USA (STARLIGHT): an open-label multi-center Ph2 trial
- 14 August 2025
- Published by Elsevier in eClinicalMedicine
- Vol. 87, 103430
Open AccessSafety and efficacy of MCO-010 optogenetic therapy in patients with Stargardt disease in USA (STARLIGHT): an open-label multi-center Ph2 trial
- Top Cited PapersOpen Access
- 23 April 2025
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 276, 350-364
Pegcetacoplan Treatment for Geographic Atrophy in Age-Related Macular Degeneration Over 36 Months: Data From OAKS, DERBY, and GALE
- 23 April 2025
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 276, 350-364
Top Cited PapersOpen AccessPegcetacoplan Treatment for Geographic Atrophy in Age-Related Macular Degeneration Over 36 Months: Data From OAKS, DERBY, and GALE
- 16 May 2024
- Published by SAGE Publications in Journal of Vitreoretinal Diseases
- Vol. 8 (4) , 394-400
Real-World Outcomes of the 0.19 mg Fluocinolone Acetonide Intravitreal Implant for Diabetic Macular Edema
Purpose: To evaluate the real-world clinical and safety outcomes of a 0.19 mg fluocinolone acetonide intravitreal implant to treat diabetic macular edema (DME). Methods: This retrospective analysis comprised patients treated with a single fluocinolone acetonide intravitreal implant for the clinical indication of ME secondary to diabetic retinopathy. Primary outcomes included changes in best-corrected visual acuity (BCVA), central subfield thickness (CST), and the frequency of DME-related treatments 12 months before and up to 36 months after fluocinolone acetonide administration. Safety outcomes were also assessed. Results: One hundred forty-eight eyes (115 patients) were followed for a mean (±SD) of 12.3 ± 4.2 months before and 29.4 ± 14.5 months after fluocinolone acetonide administration. A 0.8-letter decrease (Early Treatment Diabetic Retinopathy Study) in the mean BCVA was observed at month 24. The BCVA was 70 letters (20/40 Snellen equivalent) or more in 20.6% of eyes at baseline and in 23.7% of eyes 24 months after implant administration. The mean CST was 379.9 μm and 323.7 μm, respectively. The CST was 300 μm or less in 58.7% of eyes at month 24 ( P < .001). The mean frequency of intravitreal antivascular endothelial growth factor injections or laser photocoagulation decreased from 4.9 to 1.5 per year after fluocinolone acetonide administration ( P < .001). Implant migration to the anterior chamber occurred in 3 eyes, 2 of which were vitrectomized and later required removal. Conclusions: The 0.19 mg fluocinolone acetonide intravitreal implant provided long-term stabilization of VA and macular anatomy in patients with DME, despite a significant reduction in treatment frequency.
- 16 May 2024
- Published by SAGE Publications in Journal of Vitreoretinal Diseases
- Vol. 8 (4) , 394-400
Real-World Outcomes of the 0.19 mg Fluocinolone Acetonide Intravitreal Implant for Diabetic Macular Edema
Purpose: To evaluate the real-world clinical and safety outcomes of a 0.19 mg fluocinolone acetonide intravitreal implant to treat diabetic macular edema (DME). Methods: This retrospective analysis comprised patients treated with a single fluocinolone acetonide intravitreal implant for the clinical indication of ME secondary to diabetic retinopathy. Primary outcomes included changes in best-corrected visual acuity (BCVA), central subfield thickness (CST), and the frequency of DME-related treatments 12 months before and up to 36 months after fluocinolone acetonide administration. Safety outcomes were also assessed. Results: One hundred forty-eight eyes (115 patients) were followed for a mean (±SD) of 12.3 ± 4.2 months before and 29.4 ± 14.5 months after fluocinolone acetonide administration. A 0.8-letter decrease (Early Treatment Diabetic Retinopathy Study) in the mean BCVA was observed at month 24. The BCVA was 70 letters (20/40 Snellen equivalent) or more in 20.6% of eyes at baseline and in 23.7% of eyes 24 months after implant administration. The mean CST was 379.9 μm and 323.7 μm, respectively. The CST was 300 μm or less in 58.7% of eyes at month 24 ( P < .001). The mean frequency of intravitreal antivascular endothelial growth factor injections or laser photocoagulation decreased from 4.9 to 1.5 per year after fluocinolone acetonide administration ( P < .001). Implant migration to the anterior chamber occurred in 3 eyes, 2 of which were vitrectomized and later required removal. Conclusions: The 0.19 mg fluocinolone acetonide intravitreal implant provided long-term stabilization of VA and macular anatomy in patients with DME, despite a significant reduction in treatment frequency.
- Open Access
- 6 February 2023
- Published by Elsevier in Ophthalmology
- Vol. 130 (6) , 588-597
A Randomized Controlled Trial of OPT-302, a VEGF-C/D Inhibitor for Neovascular Age-Related Macular Degeneration
- 6 February 2023
- Published by Elsevier in Ophthalmology
- Vol. 130 (6) , 588-597
Open AccessA Randomized Controlled Trial of OPT-302, a VEGF-C/D Inhibitor for Neovascular Age-Related Macular Degeneration